Austria is in the center of Europe and has a high quality health care system. Recently there have been major changes within the insurance system which might also have longer term impact on reimbursement. Currently reimbursement pathways are seen as more pragmatic in comparison to other countries – not only in the inpatient setting. Listen and learn from the Austrian experts Dr. Stefan Walzer and Dr. Thorsten Peske.
Price negotiations in Germany – live and let die or die hard?!
Price negotiations for drugs follow clear and strict frames and rules in Germany. Anyhow, there is flexibility in terms of negotiations and price anchors including the tactical move into an arbitration board decision. Even more important is the related contract between the head association of statutory health insurance fund and the respective pharma company. The experienced negotiator Dr. Stefan Walzer and Bibiane Schulte-Bosse will discuss whether the process is a „live and let die“ or „die hard“ – from the different perspectives.
Access to German hospitals – pathways to follow
The pathway to German hospitals for medical devices, digital health applications and drugs can be straight forward in Germany. However, in the meantime there are various pathways available including the famous “NUB” and the newly introduced Hospital Future Act as well as experimental coverage and innovation fund applications. Additionally, investment goods need to differentiate between hospital ownerships.
The presenters, both long-lasting members of the Inpatient committee at the German Health Economic Association, will discuss the various pathways and applicability as well as the correlation to the annual budget negotiations of hospitals and will show the various aspects to consider when planning a launch into the German hospital setting.
MArS goes Clubhouse (again) – 10 years AMNOG
After a great webinar on “10 years AMNOG” on Thursday evening, we are happy to announce that the discussions are expanded into the German-speaking community! MArS Market Access & Pricing Strategy GmbH goes (again) to Clubhouse!! The session on April 1 2021 will be recorded and made available afterwards as well – but even better, join us and discuss directly with well-known experts: Dr. Stefan Walzer, Prof. Dr. David Matusiewicz, Bibiane Schulte-Bosse, Dr. Mathias Flume, Heiko Schellhorn, Prof. Dr. Thomas Hammerschmidt – moderation as always by Lutz Vollmer!!
Join us at Clubhouse!!
10 years AMNOG – what have we learnt for drug development and pricing?
10 years ago, the German reimbursement system for drugs changed significantly. The AMNOG including a benefit assessment and price negotiation was launched. Threats were seen, but also opportunities – the AMNOG frame was criticized and in some aspects also changed over time. A learning system – as some say.
The speakers have worked and shaped the AMNOG process also before its implementation and have also been working since the start of it in various roles and on different products. The presentation and discussions will shows the following key aspects:
- What are key success factors for a optimal AMNOG process?
- Are there any guidances for clinical development?
- How is the benefit rating and price negotiation correlated? What are drivers?
- What can we expect in the future from the AMNOG?
MArS goes Clubhouse! Digitalisation in the German health care system!?!
Are DiGAs and the Hospital Future Act sufficient to lead Germany digitally to the top?
Join the discussion at Clubhouse with our co-hosts Ariane Schenk (Bitkom), Prof. Dr. David Matusiewicz (FOM), Timo Frank (Ada Health) and Dr. Mike Christian Papenhoff (BG Klinikum Duisburg) as well as Dr. Stefan Walzer and Lutz Vollmer (both MArS).
#digitalisierung #digitalhealth #digitalhealthcare #clubhouse
The end of Covid-19 due to vaccines? By when do we have our lives back?
The covid-19 outbreak has had a significant impact on daily life of populations in the last year. Recently three pharmaceutical companies have communicated promising results of their vaccination candidates against Covid-19. Various countries in Europe have implemented vaccination programs or strategies how to set these up. Within the webinar those programs will be assessed utilizing a Covid-19 SEIR model (CovidSIM). The MArS expert team will show you in the webinar:
• Vaccination programs in Europe
• Implication of these programs from a simulation perspective
• An estimation of when the “old” normal might be the “new(set)” normal
The webinar will be held one week before Christmas. The first 24 registrations will receive a German “Gluehwein” as normally available on German Christmas markets.
The potential impact of the 2020 US presidential election on global health care pricing
The expert teams of MArS and PSE will summarize the results of the US presidential election before detailed discussions and finding on the potential health care changes and its global impact will be discussed. Most likely the potential price referencing of US prices to a global country basket will be included as other specific items.
Register now for the free webinar on November 24 2020at 9pm CET / noon PT: Register
Innovative price contracting in the German AMNOG process – is this the future or just a dream?
The presenters Dr. Stefan Walzer and Roman Spelsberg analyzed the current situation of the AMNOG process with respect to price contracting. They will show opportunities and hurdles of the current system as well as current examples. Furthermore, they will also come up with a suggestion how innovative contracting could be implemented in Germany – even further…
Register now for our new free webinar! https://us02web.zoom.us/webinar/register/3016007018391/WN_jAWzjHTbSK2m2fUXJoqLtg
Market Access & reimbursement for digital health applications
In Germany, a new market access and reimbursement process for digital health applications (DiGAs) was introduced in early 2020. In our approx. 45-minute webinar, you will learn what this new process looks like and which similar processes may exist in a European comparison. The French expert Guy Eiferman from the Market Access consulting agency Nextep will speak about the French process. The webinar will conclude with a panel discussion on the main differences and similarities between France and Germany as driving forces for digital innovation in Europe.
EU HTA to come?
There is a big debate since years on the potential implementation of a joint HTA system across Europe. Core questions on such a system remains on how such an approach could look like and even more important be implemented. The webinar will summarize the current status of the debate and also suggest a way how such a joint HTA could be implemented in the European Union.
Register now: https://us02web.zoom.us/webinar/register/4715954498495/WN_8WnsBaNyQZKf4BFvtgBP4g
Start-up failures – How can you plan for a successful market launch?
In a recent study funded by the Dutch government it was found that roughly 91% of start-ups fail! What are the reasons for that and more important how could you plan to be successful? MArS in cooperation with the Dutch consultancy Seijgraaf will present and discuss findings and solutions for a successful market access of health care start-ups. The webinar will include the following topics: • What are the major issues health care start-ups have when preparing to enter the launch? • What are must-haves in terms of market access and reimbursement for new products in the health care system? • How can a health care start-up be successful?
Webinar: Covid-19 in Europe – Germany ahead of others, but when will the second wave come and how will this potentially look like?
Germany has been seen at the forefront of the Covid-19 control and outcomes. The situation until end May is very promising with a reproduction number below one and new infections below 800 per day. Few hotspots have been identified and lock-down measures have been relaxed to a maximum. However, a core question remains: Not if, but when will a second wave of Covid-19 come and how will this potentially look like.
The MArS Covid-19 task force will present to you some realistic simulation scenarios based on epidemiological evidence.